Buffalo, New York — [Dec. 17, 2025] — Nissha Co., Ltd. today formally announced the appointment of Brandon Hoffman as Chief Executive Officer of Nissha Medical Technologies (NMT) and Michael Memminger as Chief Operating Officer and Chief Financial Officer.
These leadership changes reinforce Kyoto, Japan-based Nissha Co.’s commitment to NMT as a core growth platform within Nissha Co.’s global portfolio.
Hoffman and Memminger bring more than two decades of experience within the Nissha organization, and deep expertise across NMT’s worldwide operations. They will lead the next phase of strategic expansion, operational excellence, and long-term investment.
“Our parent company, Nissha, remains steadfast in its support of NMT as a key growth driver, including continued operations at our global headquarters in Buffalo, New York,” said Hoffman. “We have a strong team, a clear strategic direction, and a shared vision to accelerate innovation and deliver exceptional value to our customers worldwide.”
Under Hoffman’s leadership, NMT will continue to advance its position as a trusted partner in the design, development, and manufacturing of single-use medical technologies—combining technical expertise with innovative solutions to enable customer success.
“I look forward to taking on this expanded role and continuing the successful growth trajectory of NMT,” Memminger added. “Our focus will remain on operational discipline and leveraging our global capabilities to meet evolving customer needs.”
About Nissha Medical Technologies
Nissha Medical Technologies (NMT) is a global leader in medical device design and manufacturing, specializing in innovative patient monitoring and surgical solutions. With manufacturing operations worldwide, NMT is committed to advancing healthcare through precision engineering and employee development as a global CDMO.
U.S. headquartered Nissha Medical Technologies is the medical devices business unit and wholly owned subsidiary of Nissha Co. Ltd. , a Japanese publicly held company based in Kyoto, Japan (TSE:7915). NMT operates a diverse global manufacturing footprint as a med tech CDMO.
